Background: Egypt started a national treatment program intending to provide cure for Egyptian HCV-infected patients. Yet, with the development of highly-effective direct acting antivirals (DAAs) for HCV, elimination of viral hepatitis has become a real possibility. This study aimed to to evaluate the impact of DAAs on achievement of improvement in liver fibrosis, and to evaluate risk factors associated with progression of liver fibrosis in patients achieved sustained virological response (SVR). Method: the study included 300 patients diagnosed with chronic HCV infection started their treatment protocol form 2016 who were divided into two groups; Group I included patients who received Sofosbuvir + Simeprevir ± Ribavirin as dual or triple therapy (for 12 weeks) for HCV treatment, and Group II included patients who received Sofosbuvir + Daclatasvir ± Ribavirin as dual or triple therapy (for 12 weeks) for HCV treatment. All cases were subjected to complete history taking, thorough physical examination, routine laboratory investigations, pelviabdominal US together with transient elastography were ordered for all cases. Results and conclusion: both HCV treatment regimens showed improvement in liver fibrosis, fibro scan parameters showed a significant decrease in both groups compared to the baseline. There was a significant negative correlation between fibro scan parameter decrease with age, BMI, and HbA1C levels. There was no difference in degree of improvement of liver fibrosis between both regimens.